Understand the source comparison
Melatonin Contraindications: Clinical vs Research Use Comparison
Autoimmune disorders (lupus, MS, RA) High. May trigger flares via Th1 activation Moderate. Acceptable under immune monitoring Baseline and 4-week cytokine panel; discontinue if antibody titers rise Contraindicated in active disease; relative contraindication i
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Autoimmune disorders (lupus, MS, RA)
- High. May trigger flares via Th1 activation
- Moderate. Acceptable under immune monitoring
- Baseline and 4-week cytokine panel; discontinue if antibody titers rise
- Contraindicated in active disease; relative contraindication in remission without specialist clearance
- Anticoagulant or antiplatelet therapy
- Moderate. Bleeding time prolongation documented
- Low. Acceptable with coagulation monitoring
- Baseline PT/INR or platelet function test; repeat at 2 weeks
- Absolute contraindication with dual antiplatelet therapy; relative with single-agent warfarin if INR monitored
- Pregnancy or lactation
- Absolute. Placental transfer and milk secretion confirmed
- Absolute. No research justification overrides fetal/infant risk
- N/A. Avoid entirely
- No safe dose or trimester; category C rating reflects lack of human safety data, not safety confirmation
- Pediatric use (age <3 years)
- High. Endocrine development disruption risk
- Moderate. Acceptable only under pediatric endocrinology or sleep specialist
- Baseline and 6-month Tanner staging, GnRH stimulation test if puberty delayed
- Contraindicated without specialist; benefits rarely outweigh pubertal delay risk in neurotypical children
- Severe hepatic impairment (Child-Pugh C)
- High. Reduced clearance increases plasma exposure 3–5×
- Moderate. Acceptable with dose reduction to ≤1mg
- Baseline and monthly LFTs; reduce dose by 50–75%
- Relative contraindication; melatonin undergoes hepatic first-pass metabolism via CYP1A2. Impairment raises AUC significantly
- Seizure disorders
- Moderate. Mixed evidence on seizure threshold
- Low. Controlled trials show no increased seizure frequency
- Baseline EEG optional; patient diary for breakthrough seizures
- Not an absolute contraindication but requires neurologist involvement; some reports of lowered threshold, others show protective effects